patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.

progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.

patients scheduled for treatment with everolimus.

patients with at least one measurable lesion at baseline.

patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.

patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).

patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.

patients unwilling or unable to comply with the protocol.

other protocol-defined inclusion/exclusion criteria may apply.